Collaborative Breakthrough by NCKU Cancer-Cardiology Team: New Drug Proven Effective in Preventing Cardiotoxicity from Cancer Treatments

The Cardiology Department, Division of Medical Oncology, and Breast Surgery Department at National Cheng Kung University Hospital (NCKU Hospital) have successfully completed the world’s first Phase II clinical trial using a next-generation heart failure drug—Angiotensin Receptor-Neprilysin Inhibitor (ARNI)—to prevent cancer therapy-related cardiac dysfunction (CTRCD). This collaborative research marks a major step forward in achieving safer and more effective integrative care for cancer patients.